Last reviewed · How we verify
Comparator: Modified Process Vaccine
A modified process vaccine that stimulates the immune system to recognize and respond to specific disease antigens through an altered manufacturing or formulation approach.
At a glance
| Generic name | Comparator: Modified Process Vaccine |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Modified process vaccines represent an investigational approach where the manufacturing, processing, or formulation of a vaccine is altered compared to standard methods, potentially to improve immunogenicity, stability, or safety profile. The exact mechanism depends on the specific modification employed and the target antigen, but generally aims to enhance immune recognition and response.
Approved indications
Common side effects
Key clinical trials
- Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060) (PHASE3)
- Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED) (PHASE3)
- Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED) (PHASE3)
- Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) (PHASE2)
- Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Modified Process Vaccine CI brief — competitive landscape report
- Comparator: Modified Process Vaccine updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI